Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Product Type, Process & End-User The global hemodynamic monitoring systems market will witness a robust CAGR of 6.73%, valued at $1.67 Billion in 2023, expected to appreciate and reach $2.63 Billion by 2030, confirms Strategic Market Research. Hemodynamic monitoring is defined as the assessment of a patient's circulatory status. It includes the accurate measurements of intra-arterial pressure, pulmonary artery, heart rate, pulmonary capillary wedge pressures, cardiac output, blood volume, and central venous pressure. On the other hand, is also regarded as the cornerstone of perioperative anesthetic monitoring. The market is driven by a number of factors, including the growing geriatric population, the prevalence of diabetes and cardiovascular diseases, the introduction of more inventive and non-invasive devices, extensive research and development (R&D) activities, and the rising cost and concern for healthcare in the wake of the COVID-19 pandemic. Globally, cardiovascular diseases account for nearly 17.9 million deaths annually, making them the primary cause of death. In addition, 1 in every 10 individuals, or 537 million, had diabetes in 2021. By 2030 and 2045, this figure is predicted to increase to 643 million and 783 million, respectively. The demand for improved quality of life, higher patient safety, and growing awareness of the importance of healthy heart function drive the global market for hemodynamic monitoring systems. Market Dynamics Market Drivers - Technological advancements in hemodynamic monitoring systems Technological advancements have resulted in the development of more sophisticated hemodynamic monitoring devices. The use of these systems in clinical settings is fueled by their improved accuracy, dependability, and efficiency in monitoring patient vitals. For instance, micro- and nanoelectromechanical systems (MEMS/NEMS) make designing more comfortable, compact sensors for ongoing observation possible. Furthermore, hemodynamic monitoring procedures have evolved to minimize infection and pain hazards for patients due to which non-invasive methods have gained popularity. New non-invasive technologies, such as bioimpedance and pulse contour analysis, have been developed to evaluate a patient's hemodynamics precisely without invasive procedures. Thus, technological advancements have significantly stimulated market demand and growth rate. · Cardiovascular illnesses are becoming more common worldwide due to lifestyle changes and the growing aging population. Hemodynamic monitoring systems play a critical role in managing and treating these disorders. Therefore, the demand for these systems is increasing significantly. Worldwide, cardiovascular disease is the primary cause of death for both men and women, accounting for 17.9 million deaths annually. The global population is aging rapidly. Cardiovascular disorders, like coronary artery disease, hypertension, heart failure, and arrhythmias, are significantly more likely to develop in older people. According to the United Nations, by 2050, there will be more than 2.1 billion people aged 60 or older. Therefore, the rising incidence of cardiovascular disease will significantly boost the demand for the hemodynamic monitoring system market. These are some of the key reasons that are driving the overall growth of the market. Restraints - Restraint Risks associated with invasive hemodynamic monitoring The market for hemodynamic monitoring is expanding; however, there are obstacles. Some healthcare facilities may find it difficult to deploy these sophisticated systems due to their high costs and a shortage of trained personnel to operate them. Opportunities: There are many different healthcare settings where hemodynamic monitoring systems are used, such as ambulatory care facilities, cardiac catheterization labs, and home healthcare settings. These applications present lucrative opportunities for market development. In critically ill patients, hemodynamic monitoring is essential because it provides data in real-time for ongoing assessment and treatment. Home-based monitoring enables better disease management and early diagnosis of problems for patients with chronic heart failure or other illnesses. According to a 2021 study published in Critical Care Medicine, there was a 41% rise in ICU admissions worldwide between 2000 and 2010, underscoring the necessity of sophisticated monitoring methods. Furthermore, the World Health Organization projects that chronic illnesses account for more than 70% of fatalities globally, underscoring the need for home-based monitoring programs. The market for hemodynamic monitoring systems is poised for significant growth as a result of this move towards broader applicability in diverse healthcare settings. Global Hemodynamic Monitoring Systems Market Segmentation Analysis By Product Monitoring devices Disposables By Type Invasive Minimally Invasive Non-Invasive By End-User Hospitals Catheterization laboratories Others By Region North America U.S. Canada Mexico Europe Germany France Italy Switzerland UK Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific LAMEA Brazil Israel South Africa Saudi Arabia Rest of LAMEA In terms of product, the monitoring devices segment dominated the overall hemodynamic monitoring devices market, accounting for approximately 26.08% of the entire global market value in the year 2020. Some of the key reasons for this dominance are the rise in the occurrences of various cardiovascular diseases such as stroke and congestive heart failure on an annual basis throughout the world. Based on Type, the Non-invasive devices are expected to anticipate the fastest growth over the projected timeframe. It is due to the factors like the rising development initiatives of the product and the increasing demand for these technologies by the patients. In the year 2020, hospitals held an overall market percentage of above 40.0% shares. Moreover, its dominance is anticipated to exist over the next few years. It is due to the rising growth and development of innumerable portable and non-invasive monitoring devices, home care settings, various ambulatory services and the rising usage in the speciality clinics and many more. In the year 2020, Europe, as well as North America, possessed the maximum amount of share of the entire Market. Some of the prime factors that are augmenting the growth of the market in these regions are like increase in the ageing population, a rise in the incidences and prevalence of patients with lifestyle diseases, and well-established reimbursement policies along with the high purchasing power of the customers. On the other hand, the Asia-Pacific region possessed the fastest CAGR globally throughout the forecasted year. Global Hemodynamic Monitoring Systems Market Competitive Landscape Analysis The competitive landscape analysis provides information about the crucial competitors prevailing in the worldwide market environment. The comparison is performed based on overall revenue generation, market initiatives, company overview, investment in R&D, company financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, market potential, etc. Tensys Medical Inc. Koninklijke Philips NV LiDCO Group PLC GE Healthcare Edwards Lifesciences Corporation Getting AB ICU Medical Inc. Baxter (Cheetah Medical Inc.) Schwarzer Cardiotek GmbH. Deltex Medical PULSION Medical System SE CNSYSTEMS MEDIZINTECHNIK GMBH Care Taker Medical OSYPKA Medical GMBH Cheetah Medical Uscom Hemodynamic Monitoring Systems Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 1.47 Billion The revenue forecast in 2030 USD 14.12 Billion Growth rate CAGR of approximately 6.73% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Type, By End-User, By Region By Product Monitoring devices, Disposables By Type Invasive, Minimally Invasive, Non-Invasive By End-User Hospitals, Catheterization laboratories, Others By Region North America, Europe, Asia-Pacific, LAMEA Country Scope United States of America, Mexico, United Arab Emirates, United Kingdom, Germany, France, Canada, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, South Africa Company Usability Profiles Tensys Medical Inc., Koninklijke Philips NV, LiDCO Group PLC, GE Healthcare, Edwards Lifesciences Corporation, Getting AB, ICU Medical Inc., Baxter (Cheetah Medical Inc.), Schwarzer Cardiotek GmbH., Deltex Medical, PULSION Medical System SE, CNSYSTEMS MEDIZINTECHNIK GMBH, Care Taker Medical, OSYPKA Medical GMBH, Cheetah Medical, Uscom Recent Development In October 2023, Masimo announced that the LiDCO board-in-cable module had received the CE mark under the European Union Medical Device Regulation. LiDCO BIC module connects to Masimo Root for better hemodynamic monitoring. With this solution, physicians may quickly integrate LiDCO hemodynamic monitoring into their Root patient monitoring hubs, utilizing its unique and adaptable PulseCO algorithm. The LiDCO module provides a wide range of features, including rich trending data and notifications for beat-by-beat pressure analysis that may be shown on the Root monitor in the most beneficial configurations for each patient, as well as powerful guided protocols that are intended to assist in assessing fluid responsiveness. LiDCO hemodynamic monitoring and Masimo rainbow Pulse CO-Oximetry together have the potential to yield important new insights into patient status. Leading global healthcare solutions and technology provider, Mindray specializes in ultrasound, patient monitoring, and anesthesia. In October 2023, the company announced a major advancement in partnership with Edwards Lifesciences, a global leader in developing medical treatments for structural heart disease and critical care monitoring. With the seamless integration of Edwards' FloTracTM sensor for hemodynamic monitoring, Mindray's BeneVision N-Series patient monitoring system becomes the first in the North American market, marking a revolutionary achievement. Through the provision of complete monitoring systems, this relationship demonstrates the dedication of both businesses to improving patient care. With the help of reliable, scientifically supported technology, these solutions enable medical personnel to better meet hospital acute care needs while enhancing patient safety. In January 2023, Canon Medical Systems USA, a subsidiary of Canon Medical Systems Corp., formed a strategic alliance with ScImage, a healthcare technology company headquartered in California, to enhance the company's market share in the cardiovascular industry. Canon Medical Systems Corp. and Fysicon aim to expand Canon's hemodynamics footprint by dedicating more time and resources to Fysicon's QMAPP Hemodynamics solutions. Frequently Asked Question About This Report Which is the leading product for the market? Monitoring devices are the leading product for the market. Who are the essential players in market? The most vital players in the market are Schwarzer Cardiotek GmbH, Tensys Medical Inc., Koninklijke Philips NV, LiDCO Group PLC, GE Healthcare, Edwards Lifesciences Corporation, Getting AB, ICU Medical Inc., Baxter (Cheetah Medical Inc.) How big is the hemodynamic monitoring market? The global hemodynamic monitoring market is expected to grow at a compound annual growth rate (CAGR) of 6.73% from 2021 to 2030 to reach USD $ 2.64 billion by 2030. What is the global hemodynamic monitoring systems market growth? The global hemodynamic monitoring systems market is expected to grow at a compound annual growth rate (CAGR) of 6.73% from 2021 to 2030 to reach USD 2.64 billion by 2030. Which is the leading type for the market? Non-invasive devices are the leading type for the market. Sources https://www.baxter.com/sites/g/files/ebysai3896/files/2019-09/Baxter%20Announces%20Acquisition%20of%20Cheetah%20Medical%20Press%20Release.pdf https://fiftheye.com/wp-content/uploads/2021/03/20210302-fda-de-novo-grant_mar-release_final.pdf 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Hemodynamic Monitoring Market 4.2.1 Global Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, By Region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 Market, By Product, 2021 - 2030 (USD Million) 4.5 By Type Business Analysis 4.5.1 Market, By Type, 2021 - 2030 (USD Million) 4.6 By End-User Business Analysis 4.6.1 Market, By End-User, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 PEST analysis 4.9.2 Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. By Product Analysis 5.11.1. Trends in By Product (2014-2021) 5.11.2. Trends in By Product (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Collaborative Robot Manufacturing Sites, Area Served, Product Payload 6.3. Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Monitoring devices 7.3.1. Monitoring devices market, 2021 - 2030 (USD Million) 7.4. Disposables 7.4.1. Disposables market, 2021 - 2030 (USD Million) 8. Global Market: By Type Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Invasive 8.3.1. Invasive Market, 2021 - 2030 (USD Million) 8.4. Minimally Invasive 8.4.1. Minimally Invasive, 2021 - 2030 (USD Million) 8.5. Non-Invasive 8.5.1. Non-Invasive, 2021 - 2030 (USD Million) 9. Global Market: By End-User Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Hospitals 9.3.1. Hospitals market, 2021 - 2030 (USD Million) 9.4. Catheterization Laboratories 9.4.1. Catheterization Laboratories market, 2021 - 2030 (USD Million) 9.5. Others 9.5.1. Others market, 2021 - 2030 (USD Million) 10. Global Market: Regional Outlook 10.1 North America 10.1.1. North America By Product, 2021 - 2030 (USD Million) 10.1.2. North America By Type, 2021 - 2030 (USD Million) 10.1.3. North America By End-User, 2021 - 2030 (USD Million) 10.1.4. North America By Country, 2021 - 2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. By Product, 2021 - 2030 (USD Million) 10.1.4.1.2. U.S. By Type, 2021 - 2030 (USD Million) 10.1.4.1.3. U.S. By End-User, 2021 - 2030 (USD Million) 10.1.4.2. Canada 10.1.4.2.1. Canada By Product, 2021 - 2030 (USD Million) 10.1.4.2.2. Canada By Type, 2021 - 2030 (USD Million) 10.1.4.2.3. Canada By End-User, 2021 - 2030 (USD Million) 10.2. Europe 10.2.1. Europe By Product, 2021 - 2030 (USD Million) 10.2.2. Europe By Type, 2021 - 2030 (USD Million) 10.2.3. Europe By End-User, 2021 - 2030 (USD Million) 10.2.4. Europe By country, 2021 - 2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. By Product, 2021 - 2030 (USD Million) 10.2.4.1.2. U.K. By Type, 2021 - 2030 (USD Million) 10.2.4.1.3. U.K. By End-User, 2021 - 2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany By Product, 2021 - 2030 (USD Million) 10.2.4.2.2. Germany By Type, 2021 - 2030 (USD Million) 10.2.4.2.3. Germany By End-User, 2021 - 2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France By Product, 2021 - 2030 (USD Million) 10.2.4.3.2. France By Type, 2021 - 2030 (USD Million) 10.2.4.3.3. France By End-User, 2021 - 2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe By Product, 2021 - 2030 (USD Million) 10.2.4.4.2. Rest of Europe By Type, 2021 - 2030 (USD Million) 10.2.4.4.3. Rest of Europe By End-User, 2021 - 2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific By Product, 2021 - 2030 (USD Million) 10.3.2. Asia Pacific By Type, 2021 - 2030 (USD Million) 10.3.3. Asia Pacific By End-User, 2021 - 2030 (USD Million) 10.3.4. Asia Pacific By country, 2021 - 2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China By Product, 2021 - 2030 (USD Million) 10.3.4.1.2. China By Type, 2021 - 2030 (USD Million) 10.3.4.1.3. China By End-User, 2021 - 2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India By Product, 2021 - 2030 (USD Million) 10.3.4.2.2. India By Type, 2021 - 2030 (USD Million) 10.3.4.2.3. India By End-User, 2021 - 2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan By Product, 2021 - 2030 (USD Million) 10.3.4.3.2. Japan By Type, 2021 - 2030 (USD Million) 10.3.4.3.3. Japan By End-User, 2021 - 2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea By Product, 2021 - 2030 (USD Million) 10.3.4.4.2. South Korea By Type, 2021 - 2030 (USD Million) 10.3.4.4.3. South Korea By End-User, 2021 - 2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC By Product, 2021 - 2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC By Type, 2021 - 2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC By End-User, 2021 - 2030 (USD Million) 10.4. Latin America 10.4.1. Latin America By Product, 2021 - 2030 (USD Million) 10.4.2. Latin America By Type, 2021 - 2030 (USD Million) 10.4.3. Latin America By End-User, 2021 - 2030 (USD Million) 10.4.4. Latin America By country, 2021 - 2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil By Product, 2021 - 2030 (USD Million) 10.4.4.1.2. Brazil By Type, 2021 - 2030 (USD Million) 10.4.4.1.3. Brazil By End-User, 2021 - 2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico By Product, 2021 - 2030 (USD Million) 10.4.4.2.2. Mexico By Type, 2021 - 2030 (USD Million) 10.4.4.2.3. Mexico By End-User, 2021 - 2030 (USD Million) 10.4.4.3. Rest of the Latin America 10.4.4.3.1. Rest of the Latin America By Product, 2021 - 2030 (USD Million) 10.4.4.3.2. Rest of the Latin America By Type, 2021 - 2030 (USD Million) 10.4.4.3.3. Rest of the Latin America By End-User, 2021 - 2030 (USD Million) 10.5. MEA 10.5.1. MEA By Product, 2021 - 2030 (USD Million) 10.5.2. MEA By Type, 2021 - 2030 (USD Million) 10.5.3. MEA By End-User, 2021 - 2030 (USD Million) 10.5.4. MEA by Region, 2021 - 2030 (USD Million) 11. Competitive Landscape 11.1 Tensys Medical Inc 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. Product Portfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. KONINKLIJKE PHILIPS NV 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. LIDCO GROUP PLC 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. GE HEALTHCARE 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. EDWARDS LIFESCIENCES CORPORATION 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Getting AB 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. ICU Medical Inc. 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Baxter (Cheetah Medical Inc.) 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Schwarzer Cardiotek GmbH. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Deltex Medical 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. PULSION Medical System SE 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. CNSYSTEMS MEDIZINTECHNIK GMBH 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. Care Taker Medical 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. OSYPKA Medical GMBH 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. Cheetah Medical 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.16. Uscom 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development List of Tables (57 Tables) TABLE 1. By Product, 2021-2030 (USD Million) TABLE 2. FOR Monitoring devices, BY REGION, 2021-2030 (USD Million) TABLE 3. FOR Disposables, BY REGION, 2021-2030 (USD Million) TABLE 4. By Type, 2021-2030 (USD Million) TABLE 5. FOR Invasive, BY REGION, 2021-2030 (USD Million) TABLE 6. FOR Minimally Invasive, BY REGION, 2021-2030 (USD Million) TABLE 7. FOR Non-Invasive, BY REGION, 2021-2030 (USD Million) TABLE 8. BY END-USER, 2021-2030 (USD Million) TABLE 9. FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 10. FOR Catheterization Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 11. FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 12. BY REGION, 2021-2030 (USD Million) TABLE 13. NORTH AMERICA BY COUNTRY, 2021-2030 (USD Million) TABLE 14. NORTH AMERICA By Product, 2021-2030 (USD Million) TABLE 15. NORTH AMERICA By Type, 2021-2030 (USD Million) TABLE 16. NORTH AMERICA BY END-USER, 2021-2030 (USD Million) TABLE 17. EUROPE BY COUNTRY, 2021-2030 (USD Million) TABLE 18. EUROPE By Product, 2021-2030 (USD Million) TABLE 19. EUROPE By Type, 2021-2030 (USD Million) TABLE 20. EUROPE BY END-USER, 2021-2030 (USD Million) TABLE 21. ASIA-PACIFIC BY COUNTRY, 2021-2030 (USD Million) TABLE 22. ASIA-PACIFIC By Product, 2021-2030 (USD Million) TABLE 23. ASIA-PACIFIC By Type, 2021-2030 (USD Million) TABLE 24. ASIA-PACIFIC BY END-USER, 2021-2030 (USD Million) TABLE 25. LAMEA BY COUNTRY, 2021-2030 (USD Million) TABLE 26. LAMEA By Product, 2021-2030 (USD Million) TABLE 27. LAMEA By Type, 2021-2030 (USD Million) TABLE 28. LAMEA BY END-USER, 2021-2030 (USD Million) TABLE 29. Tensys Medical Inc: COMPANY SNAPSHOT TABLE 30. Tensys Medical Inc: OPERATING SEGMENTS TABLE 31. KONINKLIJKE PHILIPS NV: COMPANY SNAPSHOT TABLE 32. KONINKLIJKE PHILIPS NV: OPERATING SEGMENTS TABLE 33. LIDCO GROUP PLC: COMPANY SNAPSHOT TABLE 34. LIDCO GROUP PLC: OPERATING SEGMENTS TABLE 35. GE HEALTHCARE: COMPANY SNAPSHOT TABLE 36. GE HEALTHCARE: OPERATING SEGMENTS TABLE 37. EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT TABLE 38. EDWARDS LIFESCIENCES CORPORATION: OPERATING SEGMENTS TABLE 39. Getting AB: COMPANY SNAPSHOT TABLE 40. Getting AB: OPERATING SEGMENTS TABLE 41. ICU Medical Inc.: COMPANY SNAPSHOT TABLE 42. ICU Medical Inc.: OPERATING SEGMENTS TABLE 43. Baxter (Cheetah Medical Inc.): COMPANY SNAPSHOT TABLE 44. Baxter (Cheetah Medical Inc.): OPERATING SEGMENTS TABLE 45. Schwarzer Cardiotek GmbH.: COMPANY SNAPSHOT TABLE 46. Schwarzer Cardiotek GmbH.: OPERATING SEGMENTS TABLE 47. Deltex Medical: COMPANY SNAPSHOT TABLE 48. Deltex Medical: OPERATING SEGMENTS TABLE 49. PULSION Medical System SE: COMPANY SNAPSHOT TABLE 50. PULSION Medical System SE: OPERATING SEGMENTS TABLE 51. CNSYSTEMS MEDIZINTECHNIK GMBH: COMPANY SNAPSHOT TABLE 52. CNSYSTEMS MEDIZINTECHNIK GMBH: OPERATING SEGMENTS TABLE 53. Care Taker Medical: COMPANY SNAPSHOT TABLE 54. Care Taker Medical: OPERATING SEGMENTS TABLE 55. OSYPKA Medical GMBH: COMPANY SNAPSHOT TABLE 56. OSYPKA Medical GMBH: OPERATING SEGMENTS TABLE 57. Cheetah Medical: COMPANY SNAPSHOT TABLE 58. Cheetah Medical: OPERATING SEGMENTS TABLE 59. Uscom: COMPANY SNAPSHOT TABLE 57. Uscom: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Research Methodology Steps Figure 2 Research By Type Figure 3 Breakdown of Primaries Figure 4 Research Methodology: Hypothesis Building Figure 5 Product-Based Estimation Figure 6 Top 16 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 By Product, 2019 vs. 2025 (USD Million) Figure 9 Share, By Type, 2019 vs. 2025 (USD Million) Figure 10 Share, By End User, 2019 vs. 2025 (USD Million) Figure 11 Geographical Snapshot Figure 12 Monitoring devices to Witness Higher CAGR in Market for, By Product during Forecast Period. Figure 13 Non-invasive devices to Witness Higher CAGR in Market for By Type during Forecast Period. Figure 14 Hospitals to Witness Higher CAGR in Market for By End-User during Forecast Period. Figure 15 Asia-Pacific to Witness Higher CAGR in Market for By Region Segment during Forecast Period. Figure 17 Drivers, Restraints, Opportunities, and Challenges Figure 18 North American Snapshot Figure 19 Asia Pacific Snapshot Figure 20 Vendor Dive: Evaluation Overview